By Sheeba M. | April 18, 2026
Cannabis M&A Heats Up: 3 Takeover Targets Wall Street Is Watching
The cannabis sector is quietly positioning itself for its next major chapter. After years of overexpansion, debt restructuring, and strategic retreats, the surviving multi-state operators are now sitting on clean-enough balance sheets to resume dealmaking. And this time, the targets look different.
Why M&A Is Back on the Table
Two factors are converging to make 2026 the year M&A returns to cannabis. First, rescheduling — even in its current watered-down form — has unlocked banking access and reduced the cost of capital for compliant operators. Second, the gap between enterprise value and intrinsic asset value has widened to a point where strategic buyers can acquire revenue streams at a fraction of the cost of building them organically.
For context: the average MSO trades at roughly 1.2x EV/Revenue, compared to 3-4x for comparable consumer packaged goods companies. That’s a discount that doesn’t last when the sector fundamentals improve.
3 Stocks That Could Be Acquired in the Next 18 Months
1. Cresco Labs (CURLF)
Cresco Labs has been a consistent value creation story that the market hasn’t fully rewarded. With operations in 10 states, a strong wholesale business, and a recently simplified capital structure, CURLF looks like a logical buyout target for a larger MSO looking to quickly scale Midwest exposure. Analysts have speculated about CURLF as a target since its merger with Columbia Care closed — the integration is largely done, and the standalone thesis is running out of time.
2. Green Thumb Industries (GTBIF)
Green Thumb has been disciplined about growth relative to peers, but its retail-heavy model in mature markets like Illinois and Nevada is showing diminishing returns. GTBIF could serve as an attractive asset package for an international operator wanting instant retail scale in the U.S., though CEO Ben Railo’s continued leadership remains a key retention factor in any deal scenario.
3. Jushi Holdings (JUSHF)
Jushi is the smallest of the bunch but perhaps the most natural fit for a private equity roll-up or a strategic acquirer focused on Virginia and Pennsylvania exposure. JUSHF has been quietly restructuring its debt and asset base, and the Virginia vertical integration license is worth more in a rescheduling environment than the market currently credits.
What It Means for Your Portfolio
If you’re holding mid-tier MSO exposure, the M&A premium is currently not priced in. These stocks trade as if they’ll operate forever as independent entities — which is rarely how consolidation plays out in any sector. A strategic buyer paying even a modest premium of 20-30% to current valuations would represent meaningful upside from here.
The window for these targets won’t stay open indefinitely. As rates normalize and rescheduling creates a more favorable M&A environment, the discount embedded in these names narrows quickly. Smart money is already positioning.
Sources
- Bloomberg Cannabis Intelligence — M&A valuation multiples and deal flow analysis
- G跟着annabis Business Times — State-by-state operational performance data
- SEC Filings — Cresco Labs, Green Thumb, Jushi — Financial statements and M&A disclosures
Track cannabis M&A targets with the Weedstock Real-Time Tracker